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Abstract 
Pain which persists after healing is expected to have taken place, or which exists in the absence of tissue 
damage, is termed chronic pain. By definition chronic pain cannot be treated and cured in the 
conventional biomedical sense; rather the patient who is suffering from the pain must be given the tools 
with which their long-term pain can be managed to an acceptable level. This article will provide an 
overview of treatment approaches available for the management of persistent non-malignant pain. As well 
as attempting to provide relief from the physical aspects of pain through the judicious use of analgesics, 
interventions, stimulations, and irritations, it is important to pay equal attention to the psychosocial 
complaints which almost always accompany long term pain. The pain clinic offers a biopsychosocial 
approach to treatment with the multidisciplinary pain management programme; encouraging patients to 
take control of their pain problem and lead a fulfilling life in spite of the pain. 
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Introduction 
Pain is a common symptom of numerous medical problems, which usually indicates the occurrence of 
tissue damage. Whilst pain is unpleasant, it is also a useful mechanism with which to promote healing – 
forcing the sufferer to rest the affected area and seek out medical assistance. Pain associated with tissue 
damage, inflammation, or a disease process that is of relatively brief duration (days or weeks), is usually 
referred to as acute pain. When pain persists for extended periods of time – either as an accompaniment to 
a disease process, or following the usual amount of time expected for an injury to heal – it is referred to as 
‘chronic pain’ [1]. The International Association for the Study of Pain (IASP) have defined chronic pain 
as that which lasts for longer than three months [2]. The pain persists long after it can serve any useful 
function and is no longer just a symptom of injury or disease but a medical problem in its own right [3]. 
‘Chronic pain’ describes a syndrome characterised by persistent physical pain, disability, emotional 
disturbance, and social withdrawal symptoms existing together and influencing one another in what 
Bandura [4] termed ‘reciprocal determinism’. The source of the physical pain may be known or unknown: 
regardless, the sufferer of chronic pain will undergo a number of biological, psychological, and social 
upheavals over the course of their illness.  In order to explain such a complex syndrome as chronic pain, 
we must not become fixated on finding biomedical causes, but also consider the roles of the psychological 
and social dimensions [5]. In what Jacobson and Mariano [6] have called a ‘biopsychosocial systems 
model’, people are viewed as living systems with multiple levels of analysis ranging from the cellular to 
the social. From this perspective, all three (bio, psycho, and social) dimensions of the model are given 
equal importance in their influence on personal experience.  
Following this biopsychosocial approach, we may expect to find that treatments for chronic pain are a 
mix of medical, physical, and psychological components. Such treatments do exist in the context of a pain 
clinic, where several disciplines of pain treatment are delivered simultaneously. However, patients are 
seldom referred to multidisciplinary treatment as soon as their pain becomes chronic [7]. More often, the 
patient is treated as though they are suffering from an extended period of acute pain, which means that 
numerous medications and interventions are tried and tested, with the goal of reducing the pain to an 
acceptable level. This review will describe the range of treatments which exist for the management of 
pain, in the approximate order by which they are applied to the sufferer of chronic pain.  
 
Methods 
A narrative review of studies investigating treatment approaches for the management of chronic pain was 
carried out according to published guidance on narrative reviews [8]. We searched MEDLINE and 
EMBASE up to November 2
nd
, 2015. A combination of MESH and free text terms was employed 
including pain, chronic pain, analgesics, opioids, neuromodulation. Studies were selected for inclusion if 
examining treatments for the management of chronic pain. The search was restricted to articles published 
in English. A hand-search of the reference lists of studies meeting the inclusion criteria was also 
performed. 
 
Analgesic Medication for Pain 
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Conventional oral analgesics are always the first treatment given; they can be a fast, cheap, and relatively 
safe solution to the problem of pain. There are also a large number to choose from. In treating a case of 
pain the physician usually follows the steps on the World Health Organisation (WHO) analgesic ladder 
(Figure 1) [9]. Initially developed for the treatment of cancer pain, but applicable to most pain conditions, 
the ladder suggests that analgesic medications should be given orally with increasing dose and potency 
until pain relief has been achieved. It is a simple and inexpensive approach that produces pain relief in 80-
90% of cancer patients [10]. When applied to chronic non-cancer pain, patients rarely achieve long-term 
pain relief as side-effects tend to limit maximum dosage, and mean pain relief from opioids has been 
reported to be around 30% [11].  
Non-Steroidal Anti-Inflammatory Drugs 
The first step of the ladder consists of non-opioid analgesics, such as paracetamol and the non-steroidal 
anti-inflammatory drugs (NSAIDs). These act to reduce inflammation and provide pain relief, reducing 
the production of inflammatory chemicals by inhibition of the cyclooxgenase enzymes COX-1 and COX-
2. These enzymes catalyse the production of two types of eicosanoids: prostaglandins (PGs), which cause 
vasodilatation, increase vascular permeability, sensitise nociceptors, and inhibit gastric acid secretion and 
platelet aggregation; and also thromboxanes (TXs) which cause platelet aggregation and vasoconstriction. 
COX-1 is constituent to most tissues of the body, producing PGs and TXs for tasks such as 
gastrointestinal (GI) protection, maintenance of renal blood flow, and platelet aggregation [12]. By 
contrast COX-2 is mainly induced in inflammatory cells in response to damage, and is therefore chiefly 
responsible for the effects of inflammation – including pain [13]. Non-selective COX inhibitors act on 
both COX-1 and COX-2 and include aspirin, ibuprofen, and naproxen. The side-effects of these drugs are 
mainly due to their inhibition of COX-1. GI ulcers and their complications occur in 2% to 4% of patients 
on high doses [14] and for this reason they are often administered alongside a proton-pump inhibitor to 
protect the stomach lining from acid secretion. Selective inhibitors of the COX-2 enzyme (coxibs), 
including celecoxib and etoricoxib, were developed in the early 1990s and subsequent studies showed that 
pain relief could be achieved without the gastrointestinal and renal side effects of the traditional NSAIDs 
[14–16]. However, once the coxibs were in widespread use a number of controlled trials revealed a strong 
association with increased risk of serious thrombotic cardiovascular (CV) events [17–21] and many were 
withdrawn. Coxibs have since been shown to suppress COX-2 mediated production of platelet PG-I2 (an 
inhibitor of platelet aggregation) but not COX-1 mediated TX-A2 (a promoter of platelet aggregation), 
thus promoting a prothrombotic vascular state [22–24]. By contrast, the non-selective NSAIDs somewhat 
suppress platelet TX-A2 production through COX-1 inhibition; however they do vary in degree and 
duration of platelet COX-1 inhibition [25, 26] and have also been linked with an increased risk of 
thrombotic events [27]. More recent meta-analyses of long-term use of high dose NSAIDs have found 
that all increase the risk of coronary heart disease (CHD) and thrombotic CV events to some extent [28–
30] (with the exception of naproxen, which has a long lasting suppressive effect on TX-A2 production 
[25, 26]). The European Medicines Agency’s Committee for Medicinal Products for Human use (CHMP) 
guidelines contraindicate the use of coxibs in patients with CHD or stroke, and recommend caution when 
used for patients with risk factors for CHD [31]. The CHMP also concluded that the benefit-risk balance 
for non-selective NSAIDs is favourable, but emphasise judicious use based on individual patient risk 
factors [32]. If high doses of NSAIDs are required to control pain, it is sensible to make use of alternative 
treatments in the first instance rather than expose those patients to the cardiac, GI, and renal risk of long-
term use. 
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Weak and Strong Opioids 
The second step of the ladder adds weak opioids, codeine and dihydrocodeine. Opioid drugs mimic the 
effects of naturally occurring pain reducing chemicals (endorphins) which activate opioid receptors in the 
central nervous system that attenuate transmission of nociceptive signals.  Long-term use (>180 days) of 
codeine carries an increased risk of CV events in older patients [33]. The third step calls for strong 
opioids, which are more potent but also have more severe side effects than weak opioids. Opioids 
suppress nerve activity via activation of G-protein coupled opioid receptors which promote K
+ 
(causing 
hyperpolarisation) and inhibit Ca
2+
 (reducing transmitter release) entry into the nerve cell [12]. 
Endogenous opioid networks are involved in the regulation of many physiological functions as well as 
pain; therefore side effects always accompany administration of opioid medication. Respiratory 
depression occurs at therapeutic doses and can be fatal, so patients are always started at a low dosage 
which can be increased as tolerance develops. Also nausea, constipation, cognitive impairment, sedation 
and various hormonal effects are concerns with chronic opioid use [11]. The nervous system rapidly 
develops tolerance to the effects of opioids [34], including the analgesic effect, which means that dosage 
needs to be increased over time to achieve pain relief. Unlike the weak opioids, the effects of the 
morphine-like drugs increase as a function of dosage, therefore dose can be increased (almost 
indefinitely) to combat tolerance and rising levels of pain. In practice, patients tend to reach their own 
maximum dosage at which they can no longer accept any further increase in side effects. Recent reviews 
have suggested opioids for chronic pain have good short-term efficacy in musculoskeletal and 
neuropathic pain conditions [11], but there is less evidence for long-term efficacy beyond six months 
[35], which may be due to the effects of opioid tolerance and opioid induced pain sensitivity [36]. A 
cautious approach to dose escalation and the discontinuation of opioids if treatment goals are not met has 
been recommended [35, 36]. Despite widespread use of opioids in the treatment of fibromyalgia [37], 
there is no good quality evidence of their efficacy [38]. Opioid receptor function has been shown to be 
compromised in patients suffering with fibromyalgia [39], which may explain the poor response to 
exogenous opioids in this population. Recent work has suggested that chronic opioid use may actually 
worsen fibromyalgia symptoms [40], and Canadian [41] and German [42] guidelines strongly discourage 
their use in this condition. 
Topical analgesics 
The lipophilic opioids, fentanyl and buprenorphine, are suited for transdermal route of administration as 
they are readily absorbed through the skin, entering the blood rapidly. The use of fentanyl patches is 
associated with fewer side-effects than sustained-release oral morphine, including constipation and 
sedation, whilst providing adequate pain relief in non-cancer pain patients [43]. Buprenorphine also 
carries fewer side effects compared to oral morphine, and has been shown to be effective in a variety of 
pain conditions including osteoarthritis, low back pain, and neuropathic pain [44]. Lidocaine (an amide 
anaesthetic that inhibits nerve depolarisation through sodium channel blockade) can also be applied as a 
cream or patch to provide localised pain relief, and has been recommended for use in relief of peripheral 
neuropathic pain [45]. It is poorly absorbed across the skin so side effects are rare [46] and despite 
individual studies reporting efficacy in the relief of neuropathic pain a recent Cochrane review found no 
good quality evidence to support its use [47]. 
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Adjuvants 
The adjuvant medications referred to by the 1986 WHO analgesic ladder are ‘additional drugs... to calm 
fear and anxiety’ [9] that can be added at any step of the ladder. It should be noted that these are not the 
same as ‘adjuvant analgesics’, which are drugs with indications other than pain that may be analgesic in 
certain conditions. The terms ‘adjuvant’ and ‘adjuvant analgesic’ are conflated in pain literature; perhaps 
because anxiolytic drugs such as antidepressants and antiepileptics have since been found to be effective 
pain relievers in specific circumstances; or perhaps due to careless use of the terms which are admittedly 
very similar and easily confused. The adjuvants in the sense of the WHO ladder include anxiolytics to 
reduce pain related anxiety; hypnotics to tackle pain related insomnia; and muscle relaxants to relieve 
painful muscle spasm. These drugs may be added at any time depending on the individual needs of the 
patient. 
Adjuvant Analgesics 
Sometimes known as unconventional analgesics; drugs that were initially developed as antidepressants 
and as antiepileptics (anticonvulsants) have been found to exhibit analgesic properties when administered 
to patients with pain. The ‘+/- adjuvant’ label on the WHO ladder has come to refer to these types of 
drugs, although it is not clear if that is what it originally meant.  
In chronic pain conditions where opioid medication is often ineffective such as neuropathic pain [12] and 
fibromyalgia [38], some types of antidepressant drugs have been found to exhibit analgesic properties 
which are unrelated to their antidepressant effects. Most effective are the tricyclic antidepressants (TCAs) 
and serotonin and noradrenaline reuptake inhibitors (SNRIs), which both act to prevent reuptake of 
noradrenaline and serotonin in the brain and spinal cord. They are thought to provide analgesia by 
enhancing endogenous pain control and increasing the activity of the descending inhibitory pathway, 
however this remains unclear [48]. Selective serotonin reuptake inhibitors (SSRIs) provide little pain 
relief [45, 49, 50]. Antidepressants are often prescribed to chronic pain patients to treat comorbid 
depression and sleep problems, as well as for pain relief. After anti-inflammatory drugs and opioids, 
antidepressants are the most widely used drugs for the treatment of pain [51].  
Antiepileptic drugs can also provide analgesia in fibromyalgia and neuropathic pain patients. Gabapentin 
and pregabalin act to reduce release of excitatory neurotransmitters (including glutamate, noradrenaline, 
substance P, and calcitonin gene-related peptide [52]) from nerve terminals by inhibiting the alpha-2-delta 
subunit of the voltage-gated calcium channel [53]. Carbamazepine is effective for trigeminal neuralgia, 
but not other conditions [12]. Good quality evidence demonstrates that pregabalin an effective analgesic 
in fibromyalgia, perhaps acting to dampen central sensitisation, but this is not clear [54].  
 
Interventional Pain Management 
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The WHO pain treatment guidelines take in most of the available analgesics, however invasive 
procedures are not included. These include nerve block injections, denervation surgery, implantable drug 
delivery systems, and nerve stimulators. Invasive procedures are often risky and expensive, so they are 
usually reserved for cases that do not respond to oral and systemic analgesics. As these treatments have 
become more widely available, some authors have suggested that they be included in the pain ladder as a 
fourth step, coming after the strong opioids (e.g. [55, 56]). This would bring the 1986 pain ladder up to 
date by including more recent treatments. However, it could be argued that adding this extra step is not 
such a good idea: the 3-step ladder has persisted because it is simple and effective; it works because 
increasing the dose of a medication usually results in a reduction in pain. Adding invasive treatments as a 
fourth step might appear to condone the automatic use of these treatments. In cases where these 
treatments are unsuitable or ineffective, to use them anyway because they are the next option would be 
irresponsible, wasteful, and potentially harmful to patients. Leaving them out of the ladder reinforces the 
fact that these treatments are only suitable for use in a minority of patients, and then only after careful 
consideration. 
Nerve block injections of steroid plus local anaesthetic into the epidural space are common for back pain, 
however clinical effectiveness remains debateable. In 1995 Watts and Silagy [57] published a meta-
analysis concluding that epidural steroid injection was significantly more effective than placebo in 
providing ≥75% pain relief for up to six weeks. The number needed to treat (NNT) reveals that the level 
of pain relief was only achieved in 1 out of every 7 patients. McQuay and Moore [58] looked at the same 
data in 1998, and calculated the NNT for a more reasonable ≥50% pain relief in the short-term to be 1 in 
3. Injections into facet joints of the spine are commonly used for relief of radicular pain. Evidence for 
efficacy is limited for cervical injections and moderate for lumbar level injections [59]. The most recent 
Cochrane review of this procedure concluded that there was no strong evidence for or against the use of 
injection therapy, but did not rule out the possibility that specific subgroups of patients may respond to a 
specific type of injection [60]. 
Surgical procedures for the treatment of chronic pain have traditionally involved the destruction of 
peripheral and central nerve cells in an attempt to stop ‘pain signals’ reaching the brain. Surgery is 
invasive, irreversible, carries a high-risk of complications, and is not always effective, therefore it is often 
saved until all other pharmacological and physiological treatments have been tried without success. The 
supposed benefits of surgery rest on the principles of the now defunct specificity theory: surgery can 
interrupt the ‘pain signals’ from reaching the ‘pain centre’ in the brain. This type of surgery rarely puts an 
end to the pain, and if successful seldom offer more than temporary relief. Despite this negative 
assessment, a handful of successful cases are touted as good reason to perform surgery in those who are 
desperate enough to believe that whatever the outcome, it is preferable to their current state of suffering. 
A notable exception to the high-risk/low-success surgeries is radiofrequency denervation of facet joint 
sensory nerves, which is moderately successful for the treatment of back and neck pain caused by nerve 
irritation at the facet joints of the spine. There is moderately good evidence that it provides better pain 
relief than sham intervention, with approximately 50% of patients reporting at least 50% pain reduction 
[61]. Pain typically returns 6-12 months later; however the procedure can be repeated with similar 
efficacy and there are no reported side effects [62]. 
In contrast to these destructive procedures, pain can also be treated by surgical implantation of therapeutic 
devices into the body. Intrathecal drug delivery systems (IDDS), first implanted in 1981 [63], use a pump 
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to deliver small quantities of opioid medication directly into the cerebrospinal fluid via a catheter inserted 
into the intrathecal space. The drug is delivered at the site of action, meaning much lower doses are 
needed to achieve analgesia compared with oral opioids (ratio of dose is approximately 300:1; [64]). 
Therefore only a small amount of drug enters the circulatory system and becomes absorbed by the rest of 
the body - resulting in fewer side effects and any increase in dosage will give greater analgesia relative to 
an increase in side effects, compared to oral opioids [65]. The evidence on IDDS for chronic non-cancer 
pain is currently limited to case series and a small randomised controlled trial (RCT) which supports the 
efficacy of intrathecal opioids in long term patients [66]. Taking also into account its invasive nature, high 
initial cost and risk of complications, this technology is not regularly used. 
Spinal Cord Stimulation 
An alternative to interrupting nerve transmission with drugs is to use electrical stimulation delivered by 
electrodes placed next to the spinal nerves in the dorsal epidural space. Developed as a clinical 
application of gate control theory [67], spinal cord stimulation (SCS) delivers an electric field to the 
dorsal horn and dorsal column axons, which inhibits activity in the spinothalamic tract [68]. The patient 
experiences paraesthesia over the area served by the SCS affected nerves, which is matched to the painful 
area by altering the position and settings of the electrodes during implantation. The stimulator unit is 
implanted subcutaneously and can be reprogrammed remotely by the physician. Recent developed 
rechargeable SCS devices allow the patient to recharge the unit and also increase the longevity of the 
device. Due to high initial cost and risk of complications, SCS is usually reserved for patients who do not 
respond to other less invasive forms of treatment. SCS is currently recommended by NICE in the UK for 
use in chronic pain of neuropathic origin continuing over six months despite standard treatments [69]. 
Treatment effects tend to diminish over time: in one study 67% of patients reported ≥50% reduction in 
pain relief lasting more than six months [70], another study 47% had ≥50% pain relief after 24 months 
[71]. For those patients in whom SCS is beneficial, opioid medication can be reduced, there is a 
significant improvement in quality of life, and side effects are rare. A recent study [72] suggested that 
long term efficacy of SCS is related to improvements in psychological factors including depression and 
autonomous coping (control over pain, ability to reduce pain, and catastrophising), although the 
mechanism remains unclear. Despite high initial cost and uncertainty of a successful outcome, SCS can 
be an effective intervention for many patients, it is reversible in the event of complications, and the 
treatment is performed in over 14,000 patients each year worldwide [73]. 
SCS has also found success in treatment of ischaemic pain arising from peripheral arterial occlusive 
disease (PAOD), and in the alleviation of angina pain. Extensive studies (reviewed in [74]) have revealed 
that SCS acts to reduce peripheral ischaemic pain by promoting the release of neuropeptides and reducing 
the activity of α-1 adrenergic receptors, both of which result in vasodilatation; which combines with the 
suppressive effect on nociceptive transmission. SCS has been shown to promote healing of ulcers [75] 
and reduce need for amputation in lower limb PAOD [76]. The mechanisms by which SCS acts on the 
heart to relieve the pain of angina have also been studied. There is no evidence that SCS works to increase 
coronary blood flow [77, 78], but may act to redistribute blood flow [79]; and it has been suggested that 
the benefit of SCS to cardiac function comes from regulation of the intrinsic cardiac nervous system [73], 
acting to suppress arrhythmias and attenuate ST segment elevations [74]. Systematic reviews of RCTs 
using SCS in the treatment of refractory angina revealed significant improvements in exercise capacity 
and health related quality of life for those treated with SCS [80, 81]. SCS is not currently recommended 
8 
 
by NICE for use in ischaemic pain conditions such as angina due to inadequate evidence [69]. To address 
these uncertainties, a pilot RCT compared the use of SCS to current usual care management for refractory 
angina [82]. A trend toward larger improvements in both primary and secondary outcomes in the SCS 
group was observed although the study was not formally powered to compare outcomes between the 
groups. 
Deep Brain Stimulation (DBS) 
Implantation of electrodes to stimulate brain structures involved in the transmission and regulation of 
nociceptive signals (the periventricular grey matter and lateral somatosensory thalamus) is a highly 
invasive and risky treatment method that has been in experimental use since the 1950s [83]. For these 
reasons DBS is only used in carefully selected patients who have not responded to all other forms of 
treatment, however in these few cases satisfactory and lasting pain relief has been achieved in over 50% 
of patients [84, 85]. DBS is approved for use in the UK for treatment of refractory chronic pain [86], in 
Europe for neuropathic pain [87], and is not currently approved in the USA [88]. 
Repetitive Transcranial Magnetic Stimulation (rTMS) and Transcranial Direct Current Stimulation 
(tDCS) 
Non-invasive brain stimulation techniques rTMS and tDCS use equipment placed onto the scalp to induce 
activity in the underlying cortex via electromagnetic force (see [89] for review). Their use in pain is 
primarily investigational; however there is evidence for a reduction in pain when applied over the motor 
cortex for repeated sessions of 20 minutes or more in patients with fibromyalgia [90] and neuropathic 
pain [87]. Both techniques have a very few side-effects, which may include discomfort at the stimulation 
site and headache during stimulation, and are therefore worth trying first in patients who would otherwise 
undergo a surgical procedure [87]. 
 
Pain Relief by Counter-irritation 
A well known phenomenon in traditional medicine, the ‘pain inhibiting pain effect’ [91] or counter-
irritation [92] is the relief of pain by application of intense stimulation to the painful area or another area 
of the body. The mechanism of action by which pain relief is achieved depends upon the technique used. 
Transcutaneous Electrical Nerve Stimulation (TENS) and Percutaneous Electrical Nerve Stimulation 
(PENS) 
Electrical nerve stimulation via electrodes placed onto the skin (transcutaneous) or inserted into the skin 
(percutaneous) is used to treat a wide range of acute and chronic pain conditions, and is popular among 
doctors, nurses, and physiotherapists [93]. Although the use of peripheral stimulation (e.g. rubbing, 
vibration, heat, cold, and electrical) for pain relief has been known for thousands of years [94], an 
explanation for its effect was not offered until gate control theory (GCT) in 1965 [67]. Under GCT, 
peripheral stimulation activates large (Aβ) nerve fibres which activate spinal inhibitory neurons that 
attenuate small (C) fibre nociceptive activity and reduce pain. TENS has been demonstrated to inhibit 
nociception via this mechanism in animal and human studies [95]. Nash and colleagues [96] reported that 
if TENS was used for at least 30 minutes twice per day, 15% of patients achieved a 50% pain reduction 
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after one month, rising to 51% of patients after 24 months. McQuay and colleagues [97] concluded that 
TENS may be useful for chronic pain but there is no useful evidence, likely due to the fact that none of 
the RCTs included in the meta-analysis used anywhere near the doses of TENS recommended by the 
Nash study [96]. Despite lack of evidence of effect, TENS is effective for some patients and remains 
widely used. Evidence for efficacy of PENS is also limited, however at least one RCT has demonstrated 
that PENS is significantly more effective than sham intervention for short term relief of chronic pain [98]. 
Topical Capsaicin 
Capsaicin is the compound present in chilli peppers, and can be applied externally as a cream or patch. 
The application of capsaicin is painful itself, therefore it was originally believed to work by distracting 
the patient from their pain by replacing it with another pain i.e. counter-irritation [99]. It is now known 
that capsaicin binds to the transient receptor potential cation channel subfamily V member 1 (TRPV1) 
membrane receptor, causing depolarisation and the generation of action potentials, which are felt as 
burning, pricking or itching sensations [100]. After repeated applications or high concentrations of 
capsaicin, there is a loss of normal function of the nerve cell and a persistent desensitisation to noxious 
stimuli, termed ‘defunctionalisation’ [101]. Good quality evidence of the effectiveness of capsaicin has 
been difficult to gather, as the burning effect of capsaicin makes blinding almost impossible. Trials 
confirm that high concentration capsaicin (8%) is a more effective pain reliever than lower 
concentrations, if the patient can overcome the initial discomfort [102], and can reduce consumption of 
opioid medication [103]. As topical capsaicin is relatively safe, easy to use, and has the potential to 
benefit some patients, it is ‘worth a try’ in patients who are suffering long term pain, and accounted for 
over 224,000 prescriptions in the UK in 2013 [104]. 
Heat/Cold 
Superficial application of heat or cold (thermotherapy and cryotherapy, respectively) may be effective in 
providing immediate, short-term relief from pain [105]. Superficial heat helps to relax muscles that are 
tense or in spasm, and increase local circulation, thus reducing pain and stiffness [106]. Cryotherapy 
reduces muscular temperatures and acts to decrease local metabolism, inflammation, and pain [107]. The 
analgesic effect is thought to result from a decrease in nerve conduction speed and a reduction in muscle 
activity [108]. Heat and cold treatments are widely available, simple to use, cost effective, and patients 
will find out for themselves if they can benefit from them or not. 
A Possible Mechanism for Counter-irritation 
Experimental studies, in which brief noxious stimuli are applied to one area whilst another receives 
ongoing painful stimulation, shed light on a common mechanism that may subserve counter-irritation. A 
reduction in the activity of pain signalling neurons (in the spinal dorsal horn and trigeminal nuclei) when 
noxious stimuli are applied to a remote area of the body constitute a form of endogenous analgesia termed 
‘diffuse noxious inhibitory controls’ (DNIC; [109, 110]). Although the phenomenon of DNIC has only 
been observed under experimental conditions, it may explain the beneficial effects of the above methods 
of counter-irritation which have been observed in patients. 
 
Biopsychosocial Treatments 
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Up to this point, we have been discussing treatments which are essentially ‘done to the patient’, and thus 
fit into the biomedical model of pain treatment. The psychosocial health of the patient has been put to one 
side, perhaps with the expectation that the attenuation of pain will bring about an improvement in mental 
health and quality of life. However, chronic pain is as much a psychosocial problem as it is a 
physiological one: anxiety, depression, stress, anger, insomnia, suicide, loss of financial independence, 
disability, and family instability are closely associated with long-term pain. The neuromatrix theory [111] 
suggests that in the absence of overt physical damage, it is the psychological factors of emotion and 
cognition that contribute most to the experience of pain. In turn, these psychological factors are 
influenced by the social and cultural environment in which the patient is living, and perhaps also by side 
effects of pain reducing medications. The multiple aspects of the pain experience call for a complex form 
of treatment that can simultaneously address biological, psychological, and social issues. Such treatment 
draws on the knowledge of several healthcare disciplines including physicians, psychologists, specialist 
nurses, physiotherapists, and occupational therapists; combining to deliver what is known as 
multidisciplinary pain management. In a survey of chronic pain patients in 15 European countries and 
Israel, 23% reported they had been to see a pain management specialist [112]. In the UK, a patient will be 
referred by their general practitioner to the local pain clinic (of which there were 214 in 2010 [113]) for 
multidisciplinary treatment. On entering the pain clinic system the patient meets individually with each 
member of the team in order to discuss their situation and how treatment should proceed.  
Physiotherapy 
The goal of physiotherapy for chronic pain is to maximise and maintain the patients’ functional ability, 
without contributing to any increase in pain. Passive modalities are less likely to be used, as they are 
believed to reinforce dependence on external factors when the patient should be encouraged to take 
responsibility for their own improvement [114]. Patients are taught that pain does not necessarily imply 
that tissue damage is taking place, and that avoiding activity can actually worsen pain in the long run 
through deconditioning. The physiotherapist may also help to validate the patient’s condition, explaining 
that results of physical examinations, magnetic resonance imaging (MRI) scans, and other diagnostic tests 
often correlate poorly with pain severity and should not be relied upon as a measure of disability. Physical 
treatment is based on a set of stretches and light aerobic exercises performed on a daily basis, to regain 
muscle strength and improve range of movement that can be performed without exacerbating pain. A 
review of exercise therapy for chronic low-back pain concluded that it is slightly effective at decreasing 
pain and improving function [115]. 
Occupational Therapy 
Occupational therapy interventions focus on increasing physical capacities, mastery of self and 
environment through activities, and productive and satisfying performance of life tasks and roles [116]. 
Patients are taught early on that rest is not a good way to deal with chronic pain, and that the performance 
of a baseline level of daily activity is the key to recovery. The therapist works with the patient to 
determine the amount of activity that can be performed without exacerbating the pain. Patients’ keep a 
‘pain diary’ noting the types of activity, duration, and pain level they experience throughout the day; 
which can help the patient observe what they are doing to worsen their pain.  Activities are planned in 
advance, including regular breaks for rest – a technique known as ‘pacing’. Adaptive equipment may also 
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be required for the patient to perform tasks, for example, a perching stool allows patients’ to sit during 
tasks such as food preparation or washing up. 
Pain Specialist Nursing 
The nurse specialising in pain can advise patients on their medications, explaining the reasons why they 
have been prescribed, and suggesting the best time of day to take them to minimise the impact of side 
effects. Patients can be confused and worried when they are prescribed an antidepressant for their pain, 
which may lead to non-compliance; if patients understand why they are taking particular medications, 
they are more likely to take them [117].  
Clinical Psychology 
 The clinical psychologist is concerned with the impact that the pain condition has on the mental health 
and wellbeing of the patient. Initial assessment involves psychological screening to ascertain how the pain 
has affected mood, sleep, appetite, motivation, daily activities, relationships, work, and finances. Patients’ 
may be unsure why they are seeing a psychologist for pain treatment; it somehow implies that their pain is 
a psychological rather than a physical problem. The psychologist must take care to explain the role of 
non-physiological factors in the maintenance of pain symptoms and their responses to treatment [118]. Of 
vital importance to recovery are the ways in which the patient reacts to, and copes with physical pain and 
the emotional suffering that accompanies it. There are numerous approaches to psychological treatment: 
motivational interviewing, psychodynamic psychotherapy, operant therapy, cognitive-behavioural 
therapy, biofeedback, hypnosis, graded exposure, mindfulness based stress reduction, acceptance and 
commitment therapy, solution-focused brief therapy, and others. In a pain clinic setting, patients are often 
invited to attend a group therapy programme which combines elements of psychological treatment from 
various approaches with physiotherapy, occupational therapy, information on medication, pain 
physiology, sleep hygiene, local support groups, and relaxation techniques.  
Patients may continue to meet regularly with team members to receive ongoing treatment and monitor 
progress, however it is likely that the patient will eventually be recommended to attend a series of group 
treatment sessions known as the pain management programme (PMP) of which there were 97 in the UK 
in 2013 [119], and approximately 150 in the USA in 2011 [120]. 
 
Multidisciplinary Pain Management Programmes 
PMPs are based on the biopsychosocial model, in which behaviours are believed to reflect a combination 
of: physical events, the recognition and appraisal of these events, affective responses to these events, and 
environmental influences [121]. The programme addresses all of these components simultaneously. 
Typically, patients are treated in groups of 5-15, over a course of 8-12 sessions taking place once or twice 
a week on an outpatient basis. The group format normalises the experience of pain and maximises 
opportunities to draw on the experiences of group members; it is also cost effective ([122], p.8). Sessions 
last 3-4 hours and consist of physical, psychological, medical, and occupational themes. Each session will 
generally proceed using the same structure of five components, the contents of which change from session 
to session: exercise, education, skills training, relaxation, and homework. Pain management programmes 
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tend to differ according to the psychological approach upon which they are based, and two of these 
approaches will be discussed now. 
Cognitive-Behavioural Therapy (CBT) 
Under the cognitive-behavioural approach, individuals are not seen merely as passive responders to their 
environment, but as active processors of information, basing their responses on their own personal version 
of reality – which is constantly being revised and updated through sensory, emotional, social, 
environmental, and cognitive factors [123]. Over the lifetime, individuals learn ways of interpreting these 
factors as they are added to their version of reality, some of which may be viewed as positive, and some 
negative. It is the negative, or maladaptive, ways of thinking, feeling, and behaving that are the targets of 
CBT. Patients are taught to become aware of the connections between thoughts, feelings, and behaviours 
– to recognise that negative thoughts and feelings about the pain are directly linked to maladaptive 
behaviours and exacerbation of symptoms [124]. Unrealistic or unhelpful thoughts about pain and pain 
catastrophising are identified and replaced with thoughts oriented towards adaptive behaviour and 
positive functioning, through cognitive restructuring. Pain symptoms themselves are reconceptualised 
during the therapy process, with patients learning that they can control their symptoms to an extent by 
employing the cognitive and behavioural skills acquired during therapy [125]. 
The success or failure of CBT relies on the patient entering into a collaborative effort with the therapy 
team; they must be willing to reveal personal thoughts and feelings, and be prepared to take responsibility 
for their own well being by making every effort to put the skills they have learned into practice on a daily 
basis. It is likely that patients will initially hold the view that their pain is a medical problem and should 
be treated as such – by medications, manipulations, and surgery. It is therefore vital that this view is 
challenged at the outset, that the therapist takes time to explain the rationale of CBT, and that the patient 
understands their role in the treatment process. However, the patient should not be given false hope by 
being told that if they unquestioningly do everything asked of them, their pain will be cured, rather the 
patient should be encouraged to approach the therapy with a sense of sceptical optimism. A number of 
meta-analytic studies present convincing evidence that psychological therapies including CBT are more 
effective in bringing about improvements in coping and mental health than pharmaceutical treatment 
alone [126–130]. It should be noted that CBT does not usually bring about a reduction in pain per se; 
however this is not a goal of the treatment so it should not come as a surprise. In cases of refractory 
angina, a programme of education and self-management using an outpatient cognitive-behavioural 
programme has been successful in reducing angina symptoms. Patients attending the programme showed 
significant improvement on measures of angina frequency and stability, quality of life, anxiety and 
depression [131]; as well as a reduction in hospital visits, and a reduction in healthcare costs [132]. 
Acceptance and Commitment Therapy (ACT) 
ACT is an approach to treatment designed around processes from the psychological flexibility model and 
based in operant theory and relational frame theory [133–137]. In contrast to CBT, thoughts, feelings, and 
behaviours are not seen as the problem which must be addressed – it is the response to these factors 
which is the target for change: it is the tendency to react in maladaptive ways and fight against the pain 
that causes suffering. The patient is encouraged to question whether their current courses of action are 
preventing them from, or helping them move towards, their life goals and values. The patient may be 
concerned with the eradication of pain in order to live a better life: the lack of pain is not the ultimate 
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goal; it is a means to an end. In chronic pain this means can never be achieved, and ACT suggests 
abandoning that means as it really presents a barrier to moving towards the goal of a better life [134]. 
ACT provides techniques that the patient can use to deal with the thoughts of pain, to minimise focus on 
reducing pain or thought content, engage in a process of defusing and letting go, and move towards their 
values and goals [134, 138]. An important technique employed to foster acceptance, to help view the self 
as separate from thoughts and emotions, and to aid defusion and letting go of automatic thoughts is 
‘mindfulness’. The essence of mindfulness is paying attention to the present moment without attaching 
meaning or judgmental language to thoughts that arise [139]. Seeing thoughts as transient events, separate 
from the self, cultivates psychological flexibility, allowing the patient to deal with difficult thoughts and 
feelings that might otherwise become barriers to pursuing their goals. ACT differs from CBT in the 
regard that it does not attempt to change thoughts and feelings: how a person has dealt with their 
problems in the past is not important. Patients can learn to use the skills taught in ACT to begin living a 
fulfilling life right away, without first ‘winning a war with [their] own history’ ([134], p.652). The use of 
ACT as a treatment approach for chronic pain problems has grown steadily over the past 15 years. During 
this time evidence has accumulated that supports the use of ACT as a good alternative to CBT, with 
similar effects on a range of treatment outcomes [140, 141]. 
 
[Table 1 about here] 
 
Conclusion 
Pain is a multidimensional problem that must be explained and treated using a combination of biological, 
psychological, and social approaches (Table 1). When it comes to the treatment of chronic pain, the 
biopsychosocial approach provides a wider scope of inquiry and intervention than a biomedical view, and 
shifts the focus of the treatment away from just physical pain relief towards strategies that increase 
functional ability and wellbeing in spite of the pain. Such treatments are crucial in ensuring that patients 
maintain a satisfactory quality of life and deal with the anxiety, depression, and social upheaval which 
accompany persistent physical pain. 
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Figure legends 
 
Figure 1. The WHO analgesic ladder (adapted from [9], p.94). 
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Table 1 
Biomedical   Biopsychosocial 
 
 
Less 
Invasive 
 
 
 
 
 
 
More 
Invasive 
 
 
 
 
 
 
Less 
Invasive 
 
Topical Analgesic 
 
Pharmaceutical 
 
 
Physiotherapy 
Oral Analgesic   
Adjuvant Analgesic  Occupational Therapy 
Nerve Block Injection   
Intrathecal DDS 
  Surgical 
 Specialist Nursing 
Nerve Section   
Deep Brain Stim.  Clinical Psychology 
Spinal Cord Stim.   
Percutaneous ENS  
Electrical 
 Cognitive Behavioural 
Transcutaneous ENS  Therapy 
Repetitive TMS  Acceptance and 
Transcranial DCS  Commitment Therapy 
 
Abbreviations used: DDS = Drug Delivery System; Stim. = Stimulation; ENS = Electrical Nerve Stimulation; 
TMS = Transcranial Magnetic Stimulation; DCS = Direct Current Stimulation 
 
